Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepa Jagadeesh

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
European Journal of Haematology|March 23, 2023
Validation of the role of corrected DLCO in predicting outcomes post autologous hematopoietic cell transplant for multiple myelomaHussein Awada, Adel Hajj Ali, Muhammad Faizan Ali, et al.
British Journal of Haematology|July 14, 2016
Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planningVan T Nguyen, Priyanka A Pophali, Judy P Tsai, et al.
Blood|August 11, 2017
A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinibAllison M Winter, Daniel J Landsburg, Anthony R Mato, et al.
Hematology/Oncology and Stem Cell Therapy|December 10, 2020
Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary eraSanghee Hong, Lisa Rybicki, Donna Corrigan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 26, 2016
Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell TransplantationBrian T Hill, Lisa Rybicki, Kelley D Carlstrom, et al.
Leukemia & Lymphoma|December 30, 2020
Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysisAgrima Mian, Wei Wei, Allison M Winter, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 5, 2019
Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple MyelomaJack Khouri, Frederic Reu, Navneet S Majhail, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 17, 2019
Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell LymphomaJessica El-Asmar, Lisa Rybicki, Brian J Bolwell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2016
Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple MyelomaSanghee Hong, Lisa Rybicki, Donna Abounader, et al.
American Journal of Hematology|April 5, 2017
The association of histologic grade with acute graft-versus-host disease response and outcomesMayur Narkhede, Lisa Rybicki, Donna Abounader, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
European Journal of Haematology|March 23, 2023
Validation of the role of corrected DLCO in predicting outcomes post autologous hematopoietic cell transplant for multiple myelomaHussein Awada, Adel Hajj Ali, Muhammad Faizan Ali, et al.
British Journal of Haematology|July 14, 2016
Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planningVan T Nguyen, Priyanka A Pophali, Judy P Tsai, et al.
Blood|August 11, 2017
A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinibAllison M Winter, Daniel J Landsburg, Anthony R Mato, et al.
Hematology/Oncology and Stem Cell Therapy|December 10, 2020
Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary eraSanghee Hong, Lisa Rybicki, Donna Corrigan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 26, 2016
Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell TransplantationBrian T Hill, Lisa Rybicki, Kelley D Carlstrom, et al.
Leukemia & Lymphoma|December 30, 2020
Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysisAgrima Mian, Wei Wei, Allison M Winter, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 5, 2019
Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple MyelomaJack Khouri, Frederic Reu, Navneet S Majhail, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 17, 2019
Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell LymphomaJessica El-Asmar, Lisa Rybicki, Brian J Bolwell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2016
Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple MyelomaSanghee Hong, Lisa Rybicki, Donna Abounader, et al.
American Journal of Hematology|April 5, 2017
The association of histologic grade with acute graft-versus-host disease response and outcomesMayur Narkhede, Lisa Rybicki, Donna Abounader, et al.
Pageof 10